Wang D Y, Xiang Y Y, Tanaka M, Li X R, Li J L, Shen Q, Sugimura H, Kino I
First Department of Pathology, Hamamatsu University School of Medicine, Japan.
Cancer. 1994 Dec 15;74(12):3089-96. doi: 10.1002/1097-0142(19941215)74:12<3089::aid-cncr2820741205>3.0.co;2-n.
Linxian is the highest endemic area of esophageal squamous cell carcinoma (ESCC) in China and one of the highest incidence areas in the world. The relationship of p53 protein accumulation to geographic variation, pathologic findings, and prognosis has not been investigated extensively.
Formalin fixed, paraffin embedded ESCC tissues from 100 patients who underwent esophagectomy between 1973 and 1983 were immunostained by using monoclonal antibody pAB1801.
p53 overexpression was observed in 41 (87.2%) of 47 tumors of patients in Linxian and in 16 (64%) of 25 additional patients outside Linxian. Its prevalence in the noncancerous epithelium (11/72, 15.3%) and carcinoma in situ (1/7, 14.3%) was lower than that in invasive lesions (64/93, 68.8%). Its immunostaining intensity increased with the depth of cancer invasion. Of 30 primary carcinomas with lymph node metastasis, 29 (96.7%) were positive. However, only 36 (51.4%) of 70 primary lesions without metastasis were positive, and a higher intensity was noticed in the metastases. There was a lower expression rate in tumors of patients surviving more than 10 years (25/52, 48.1%) than in those surviving less than 3 years (40/48, 83.3%). Overall and nonadvanced or metastasis-free cumulative survival rates were both significantly different in patients with and without p53 protein overexpression.
There is a higher expression rate of p53 protein in ESCC in tumors of patients from Linxian than in those from the surrounding area. The accumulation of p53 protein is related to the invasiveness and capability for metastases of cancer cells and appears to be a useful prognostic factor for patients with ESCC.
林县是中国食管鳞状细胞癌(ESCC)的最高发病地区,也是世界上发病率最高的地区之一。p53蛋白积累与地理差异、病理结果及预后的关系尚未得到广泛研究。
对1973年至1983年间接受食管切除术的100例患者的福尔马林固定、石蜡包埋的ESCC组织,使用单克隆抗体pAB1801进行免疫染色。
林县47例患者的肿瘤中有41例(87.2%)观察到p53过表达,林县以外的另外25例患者中有16例(64%)观察到p53过表达。其在非癌上皮(11/72,15.3%)和原位癌(1/7,14.3%)中的发生率低于浸润性病变(64/93,68.8%)。其免疫染色强度随癌症浸润深度增加。在30例有淋巴结转移的原发性癌中,29例(96.7%)呈阳性。然而,在70例无转移的原发性病变中,只有36例(51.4%)呈阳性,且转移灶中的强度更高。存活超过10年的患者的肿瘤(25/52,48.1%)的表达率低于存活不足3年的患者(40/48,83.3%)。p53蛋白过表达和未过表达的患者的总生存率以及非进展或无转移累积生存率均有显著差异。
林县患者的ESCC肿瘤中p53蛋白的表达率高于周边地区患者。p53蛋白的积累与癌细胞的侵袭性和转移能力有关,似乎是ESCC患者的一个有用的预后因素。